<?xml version='1.0' encoding='UTF-8' standalone='no'?>
<rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:bqbiol="http://biomodels.net/biology-qualifiers/" xmlns:collex="http://www.collex.org/schema#" xmlns:bqmodel="http://biomodels.net/model-qualifiers/" xmlns:scoro="http://purl.org/spar/scoro/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:biomodel="http://biomodels.net/model-qualifiers/">
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:title>Bonhoeffer, Rembiszewski, Ortiz, Nixon, 2000</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <prism:keyword>immunology</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:description>#### Model Status



 This CellML model runs in OpenCell and COR to replicate the published results (figure 2 - up until the introduction of the drug, which is not described in this set of equations). The units have been checked and they are consistent. This particular CellML model represents model 1 from the published paper.
 


#### Model Structure



ABSTRACT: BACKGROUND: Structured interruptions of antiretroviral therapy of HIV-1 infected individuals are currently being tested in clinical trials to study the effect interruptions have on the immune responses and control of virus replication. OBJECTIVE: To investigate the potential risks and benefits of interrupted therapy using standard population dynamical models of HIV replication kinetics. METHODS: Standard population dynamical models were used to study the effect of structured therapy interruptions on the immune effector cells, the latent cell compartment and the emergence of drug resistance. CONCLUSIONS: The models suggest that structured therapy interruption only leads to transient or sustained virus control if the immune effector cells increase during therapy. This increase must more than counterbalance the increase in susceptible target cells induced by therapy. The risk of inducing drug resistance by therapy interruptions or the risk of repopulating the pool of latent cells during drug-free periods may be small if the virus population remains at levels considerably below baseline. However, if the virus load increases during drug-free periods to levels similar to or higher than baseline before therapy, both these risks increase dramatically.




The original paper reference is cited below:




Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection, Sebastian Bonhoeffer, Michal Rembiszewski, Gabriel M. Ortiz, and Douglas F. Nixon, 2000,
 *AIDS*, 14, 2313-2322. [PubMed ID: 11089619](http://www.ncbi.nlm.nih.gov/pubmed/11089619)</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <collex:thumbnail rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <rdfs:label>Sebastian Bonhoeffer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <foaf:name>Sebastian Bonhoeffer</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:creator rdf:resource="local:00001">local:00001</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <rdfs:label>Michal Rembiszewski</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <foaf:name>Michal Rembiszewski</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:creator rdf:resource="local:00002">local:00002</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <rdfs:label>Gabriel M. Ortiz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <foaf:name>Gabriel M. Ortiz</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:creator rdf:resource="local:00003">local:00003</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <rdfs:label>Douglas F. Nixon</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <foaf:name>Douglas F. Nixon</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:creator rdf:resource="local:00004">local:00004</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <rdfs:label>Catherine Lloyd</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <foaf:name>Catherine Lloyd</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:contributor rdf:resource="local:00005">local:00005</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <dc:identifier rdf:resource="http://identifiers.org/orcid:0000-0001-5801-5510">http://identifiers.org/orcid:0000-0001-5801-5510</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <rdfs:label>Bilal Shaikh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <foaf:accountName rdf:resource="https://orcid.org/0000-0001-5801-5510">https://orcid.org/0000-0001-5801-5510</foaf:accountName>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <foaf:name>Bilal Shaikh</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:contributor rdf:resource="local:00006">local:00006</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <dc:identifier rdf:resource="https://identifiers.org/pmr:def2cd06391e17d8966e22997a65476a">https://identifiers.org/pmr:def2cd06391e17d8966e22997a65476a</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <rdfs:label>PMR: def2cd06391e17d8966e22997a65476a</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <bqmodel:is rdf:resource="local:00007">local:00007</bqmodel:is>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <dc:identifier rdf:resource="https://identifiers.org/doi/10.1097/00002030-200010200-00012">https://identifiers.org/doi/10.1097/00002030-200010200-00012</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <rdfs:label>Sebastian Bonhoeffer, Michal Rembiszewski, Gabriel M. Ortiz &amp; Douglas F. Nixon. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS 14, 15: 2313-2322 (2000).</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00008">local:00008</bqmodel:isDescribedBy>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:license rdf:resource="local:00009">local:00009</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex">
    <dc:created>2009-06-16T20:39:25</dc:created>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml">
    <dc:title>Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection: Model 1</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml">
    <dc:description>#### Model Status



 This CellML model runs in OpenCell and COR to replicate the published results (figure 2 - up until the introduction of the drug, which is not described in this set of equations). The units have been checked and they are consistent. This particular CellML model represents model 1 from the published paper.
 


#### Model Structure



ABSTRACT: BACKGROUND: Structured interruptions of antiretroviral therapy of HIV-1 infected individuals are currently being tested in clinical trials to study the effect interruptions have on the immune responses and control of virus replication. OBJECTIVE: To investigate the potential risks and benefits of interrupted therapy using standard population dynamical models of HIV replication kinetics. METHODS: Standard population dynamical models were used to study the effect of structured therapy interruptions on the immune effector cells, the latent cell compartment and the emergence of drug resistance. CONCLUSIONS: The models suggest that structured therapy interruption only leads to transient or sustained virus control if the immune effector cells increase during therapy. This increase must more than counterbalance the increase in susceptible target cells induced by therapy. The risk of inducing drug resistance by therapy interruptions or the risk of repopulating the pool of latent cells during drug-free periods may be small if the virus population remains at levels considerably below baseline. However, if the virus load increases during drug-free periods to levels similar to or higher than baseline before therapy, both these risks increase dramatically.




The original paper reference is cited below:




Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection, Sebastian Bonhoeffer, Michal Rembiszewski, Gabriel M. Ortiz, and Douglas F. Nixon, 2000,
 *AIDS*, 14, 2313-2322. [PubMed ID: 11089619](http://www.ncbi.nlm.nih.gov/pubmed/11089619)</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml">
    <dc:license rdf:resource="local:00010">local:00010</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml">
    <dc:title>Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection: Model 2</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml">
    <dc:description>#### Model Status



 This CellML model runs in OpenCell and COR to replicate the published results (figure 3 - up until the introduction of the drug, which is not described in this set of equations). The units have been checked and they are consistent. This particular CellML model represents model 2 from the published paper.
 


#### Model Structure



ABSTRACT: BACKGROUND: Structured interruptions of antiretroviral therapy of HIV-1 infected individuals are currently being tested in clinical trials to study the effect interruptions have on the immune responses and control of virus replication. OBJECTIVE: To investigate the potential risks and benefits of interrupted therapy using standard population dynamical models of HIV replication kinetics. METHODS: Standard population dynamical models were used to study the effect of structured therapy interruptions on the immune effector cells, the latent cell compartment and the emergence of drug resistance. CONCLUSIONS: The models suggest that structured therapy interruption only leads to transient or sustained virus control if the immune effector cells increase during therapy. This increase must more than counterbalance the increase in susceptible target cells induced by therapy. The risk of inducing drug resistance by therapy interruptions or the risk of repopulating the pool of latent cells during drug-free periods may be small if the virus population remains at levels considerably below baseline. However, if the virus load increases during drug-free periods to levels similar to or higher than baseline before therapy, both these risks increase dramatically.




The original paper reference is cited below:




Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection, Sebastian Bonhoeffer, Michal Rembiszewski, Gabriel M. Ortiz, and Douglas F. Nixon, 2000,
 *AIDS*, 14, 2313-2322. [PubMed ID: 11089619](http://www.ncbi.nlm.nih.gov/pubmed/11089619)</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml">
    <dc:license rdf:resource="local:00011">local:00011</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml">
    <dc:title>Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection: Model 3</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml">
    <dc:description>#### Model Status



 This CellML model runs in OpenCell and COR to replicate the published results (figure 4 - up until the introduction of the drug, which is not described in this set of equations). The units have been checked and they are consistent. This particular CellML model represents model 3 from the published paper.
 


#### Model Structure



ABSTRACT: BACKGROUND: Structured interruptions of antiretroviral therapy of HIV-1 infected individuals are currently being tested in clinical trials to study the effect interruptions have on the immune responses and control of virus replication. OBJECTIVE: To investigate the potential risks and benefits of interrupted therapy using standard population dynamical models of HIV replication kinetics. METHODS: Standard population dynamical models were used to study the effect of structured therapy interruptions on the immune effector cells, the latent cell compartment and the emergence of drug resistance. CONCLUSIONS: The models suggest that structured therapy interruption only leads to transient or sustained virus control if the immune effector cells increase during therapy. This increase must more than counterbalance the increase in susceptible target cells induced by therapy. The risk of inducing drug resistance by therapy interruptions or the risk of repopulating the pool of latent cells during drug-free periods may be small if the virus population remains at levels considerably below baseline. However, if the virus load increases during drug-free periods to levels similar to or higher than baseline before therapy, both these risks increase dramatically.




The original paper reference is cited below:




Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection, Sebastian Bonhoeffer, Michal Rembiszewski, Gabriel M. Ortiz, and Douglas F. Nixon, 2000,
 *AIDS*, 14, 2313-2322. [PubMed ID: 11089619](http://www.ncbi.nlm.nih.gov/pubmed/11089619)</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml">
    <dc:license rdf:resource="local:00012">local:00012</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_0.sedml">
    <dc:title>Simulation 0</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_0.sedml">
    <dc:description>Automatically generated SED-ML file for model bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <rdfs:label>CC BY 4.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_0.sedml">
    <dc:license rdf:resource="local:00013">local:00013</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_0.sedml">
    <bqmodel:isDerivedFrom rdf:resource="local:00014">local:00014</bqmodel:isDerivedFrom>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <dc:description>isDerivedFrom</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <dc:identifier rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_a.cellml</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <rdfs:label>bonhoeffer_rembiszewski_ortiz_nixon_2000_a</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_1.sedml">
    <dc:title>Simulation 1</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_1.sedml">
    <dc:description>Automatically generated SED-ML file for model bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00015">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00015">
    <rdfs:label>CC BY 4.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_1.sedml">
    <dc:license rdf:resource="local:00015">local:00015</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_1.sedml">
    <bqmodel:isDerivedFrom rdf:resource="local:00016">local:00016</bqmodel:isDerivedFrom>
  </rdf:Description>
  <rdf:Description rdf:about="local:00016">
    <dc:description>isDerivedFrom</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00016">
    <dc:identifier rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_b.cellml</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00016">
    <rdfs:label>bonhoeffer_rembiszewski_ortiz_nixon_2000_b</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_2.sedml">
    <dc:title>Simulation 2</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_2.sedml">
    <dc:description>Automatically generated SED-ML file for model bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00017">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00017">
    <rdfs:label>CC BY 4.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_2.sedml">
    <dc:license rdf:resource="local:00017">local:00017</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/simulation_2.sedml">
    <bqmodel:isDerivedFrom rdf:resource="local:00018">local:00018</bqmodel:isDerivedFrom>
  </rdf:Description>
  <rdf:Description rdf:about="local:00018">
    <dc:description>isDerivedFrom</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00018">
    <dc:identifier rdf:resource="http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml">http://omex-library.org/def2cd06391e17d8966e22997a65476a.omex/bonhoeffer_rembiszewski_ortiz_nixon_2000_c.cellml</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00018">
    <rdfs:label>bonhoeffer_rembiszewski_ortiz_nixon_2000_c</rdfs:label>
  </rdf:Description>
</rdf:RDF>
